Endocrine Abstracts

Background: The study aimed to minimize the risk causing factors and evaluate new atherosclerotic cardiovascular disease (ASCVD) risk score using Million Hearts^® Longitudinal ASCVD risk assessment tool among type 2 diabetes mellitus (T2D) patients.

Methods: A non-interventional retrospective analysis of electronic medical records of Apollo Sugar Clinics, India. A total of 365 patient’s data was collected, and were categorized into normotensive (<120-129/80, mmHg), prehypertensive (130-139/80-89, mmHg), and hypertensive (>140/90, mmHg) based on their blood pressure (BP). ASCVD risk score of each patient was calculated using Million Hearts^® Longitudinal ASCVD Risk Assessment Tool, as per ACC/AHA 2016 guidelines. Statistical analysis was done by using SPSS version 20, with significance set at 2 tailed P ≤0.05.

Results: Total 365 patients were analysed, their mean (SD) age was 52.6 (11.9) years, 63.6% were males and 36.4% were females. Of these patients 45.8%, 24.4%, and 29.9% were normotensive, prehypertensive, and hypertensive, respectively. The indicators of ASCVD risk, age, BMI, and total cholesterol (each P<0.05) were significantly different among three groups. Of the 365 patients only 161 patients who met the ASCVD risk assessment criteria the score was calculated. The 10-year baseline risk score was 16.8% and expected risk would reduce to 12.5% if statin therapy is initiated. A significant difference in risk score was observed among three groups at baseline (14.4%; 15.6%; 19.4%, P=0.05), and expected 10-year risk (10.8%; 11.6%; 14.4%, P=0.07) if statin therapy initiated.

Conclusion: Treatment of cholesterol level by moderate or high intensity statins should be an essential component of multifactorial intervention for primary prevention of CV disease in diabetes patients.